• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

体内标记显示 TCF-1+ T 细胞在肿瘤和淋巴组织之间持续迁移。

In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue.

机构信息

Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.

Molecular Immunity Unit, Department of Medicine, University of Cambridge, Cambridge, UK.

出版信息

J Exp Med. 2022 Jun 6;219(6). doi: 10.1084/jem.20210749. Epub 2022 Apr 26.

DOI:10.1084/jem.20210749
PMID:35472220
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9048291/
Abstract

Improving the efficacy of immune checkpoint therapies will require a better understanding of how immune cells are recruited and sustained in tumors. Here, we used the photoconversion of the tumor immune cell compartment to identify newly entering lymphocytes, determine how they change over time, and investigate their egress from the tumor. Combining single-cell transcriptomics and flow cytometry, we found that while a diverse mix of CD8 T cell subsets enter the tumor, all CD8 T cells retained within this environment for more than 72 h developed an exhausted phenotype, revealing the rapid establishment of this program. Rather than forming tumor-resident populations, non-effector subsets, which express TCF-1 and include memory and stem-like cells, were continuously recruited into the tumor, but this recruitment was balanced by concurrent egress to the tumor-draining lymph node. Thus, the TCF-1+ CD8 T cell niche in tumors is highly dynamic, with the circulation of cells between the tumor and peripheral lymphoid tissue to bridge systemic and intratumoral responses.

摘要

提高免疫检查点疗法的疗效将需要更好地了解免疫细胞如何在肿瘤中被招募和维持。在这里,我们使用肿瘤免疫细胞区室的光转化来鉴定新进入的淋巴细胞,确定它们随时间的变化,并研究它们从肿瘤中的流出。结合单细胞转录组学和流式细胞术,我们发现,虽然进入肿瘤的 CD8 T 细胞亚群种类繁多,但在这种环境中停留超过 72 小时的所有 CD8 T 细胞都发展出了衰竭表型,这表明该程序的快速建立。非效应亚群,包括记忆和干细胞样细胞,表达 TCF-1 并包括在内,而非效应亚群并没有形成肿瘤驻留群体,而是不断被招募到肿瘤中,但这种招募被同时向肿瘤引流淋巴结的流出所平衡。因此,肿瘤中的 TCF-1+CD8 T 细胞龛是高度动态的,细胞在肿瘤和外周淋巴组织之间循环,以桥接系统和肿瘤内反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/e31f94489e4d/JEM_20210749_FigS5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/069534f2a5f1/JEM_20210749_GA.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/cdbcba4be1a7/JEM_20210749_Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/493f472a59bc/JEM_20210749_FigS1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/eee51ab940ed/JEM_20210749_FigS2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/77e23df4de8d/JEM_20210749_Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/c62d08650695/JEM_20210749_FigS3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/2a9350a61efd/JEM_20210749_Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/1d8ccdaef6b1/JEM_20210749_Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/d7afe4e10ba4/JEM_20210749_FigS4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/579223c88214/JEM_20210749_Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/4817b9b5b786/JEM_20210749_Fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/0678d41ee797/JEM_20210749_Fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/53e012c5beb6/JEM_20210749_Fig8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/e31f94489e4d/JEM_20210749_FigS5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/069534f2a5f1/JEM_20210749_GA.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/cdbcba4be1a7/JEM_20210749_Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/493f472a59bc/JEM_20210749_FigS1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/eee51ab940ed/JEM_20210749_FigS2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/77e23df4de8d/JEM_20210749_Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/c62d08650695/JEM_20210749_FigS3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/2a9350a61efd/JEM_20210749_Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/1d8ccdaef6b1/JEM_20210749_Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/d7afe4e10ba4/JEM_20210749_FigS4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/579223c88214/JEM_20210749_Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/4817b9b5b786/JEM_20210749_Fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/0678d41ee797/JEM_20210749_Fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/53e012c5beb6/JEM_20210749_Fig8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0725/9048291/e31f94489e4d/JEM_20210749_FigS5.jpg

相似文献

1
In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue.体内标记显示 TCF-1+ T 细胞在肿瘤和淋巴组织之间持续迁移。
J Exp Med. 2022 Jun 6;219(6). doi: 10.1084/jem.20210749. Epub 2022 Apr 26.
2
Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1 CD8 T cells in tumor-draining lymph nodes.常规的 I 型树突状细胞在肿瘤引流淋巴结中维持着增殖性肿瘤抗原特异性 TCF-1 CD8 T 细胞的储备库。
Immunity. 2021 Oct 12;54(10):2338-2353.e6. doi: 10.1016/j.immuni.2021.08.026. Epub 2021 Sep 16.
3
Retention of Ag-specific memory CD4 T cells in the draining lymph node indicates lymphoid tissue resident memory populations.引流淋巴结中Ag特异性记忆CD4 T细胞的保留表明存在淋巴组织驻留记忆群体。
Eur J Immunol. 2017 May;47(5):860-871. doi: 10.1002/eji.201646681. Epub 2017 Apr 11.
4
Lymphoid tissue residency: A key to understand Tcf-1PD-1 T cells.淋巴组织驻留:理解 Tcf-1PD-1 T 细胞的关键。
Front Immunol. 2022 Dec 7;13:1074698. doi: 10.3389/fimmu.2022.1074698. eCollection 2022.
5
In vivo photolabeling of tumor-infiltrating cells reveals highly regulated egress of T-cell subsets from tumors.体内光标记肿瘤浸润细胞揭示了 T 细胞亚群从肿瘤中高度受调控的流出。
Proc Natl Acad Sci U S A. 2017 May 30;114(22):5677-5682. doi: 10.1073/pnas.1618446114. Epub 2017 May 15.
6
Memory CD8 T cell responses to cancer.癌症的记忆 CD8 T 细胞反应。
Semin Immunol. 2020 Jun;49:101435. doi: 10.1016/j.smim.2020.101435. Epub 2020 Nov 30.
7
Human effector CD8 T cells with an activated and exhausted-like phenotype control tumour growth in vivo in a humanized tumour model.人源效应性 CD8 T 细胞具有激活和耗竭样表型,可在人源化肿瘤模型中控制肿瘤生长。
EBioMedicine. 2024 Aug;106:105240. doi: 10.1016/j.ebiom.2024.105240. Epub 2024 Jul 9.
8
Induction of Progenitor Exhausted Tissue-Resident Memory CD8 T Cells Upon Typhi Porins Adjuvant Immunization Correlates With Melanoma Control and Anti-PD-1 Immunotherapy Cooperation.伤寒菌属外膜蛋白佐剂免疫诱导祖细胞耗竭组织驻留记忆 CD8 T 细胞与黑色素瘤控制和抗 PD-1 免疫治疗协同作用相关。
Front Immunol. 2020 Nov 6;11:583382. doi: 10.3389/fimmu.2020.583382. eCollection 2020.
9
Control of Lymphocyte Fate, Infection, and Tumor Immunity by TCF-1.TCF-1 对淋巴细胞命运、感染和肿瘤免疫的控制。
Trends Immunol. 2019 Dec;40(12):1149-1162. doi: 10.1016/j.it.2019.10.006. Epub 2019 Nov 14.
10
Immune checkpoints are predominantly co-expressed by clonally expanded CD4FoxP3 intratumoral T-cells in primary human cancers.免疫检查点主要由原发性人类癌症中克隆扩增的 CD4FoxP3 肿瘤内 T 细胞共表达。
J Exp Clin Cancer Res. 2023 Dec 6;42(1):333. doi: 10.1186/s13046-023-02897-6.

引用本文的文献

1
The efficacy and immune-mediated safety of PD-1/PD-L1 combined with neoadjuvant chemotherapy in triple-negative breast cancer: a meta-analysis.PD-1/PD-L1联合新辅助化疗治疗三阴性乳腺癌的疗效及免疫介导的安全性:一项荟萃分析
Front Oncol. 2025 Aug 7;15:1635418. doi: 10.3389/fonc.2025.1635418. eCollection 2025.
2
Masters of adaptation: How cancer and immune cell plasticity mediates tumor progression.适应大师:癌症与免疫细胞可塑性如何介导肿瘤进展
PLoS Biol. 2025 Jul 15;23(7):e3003301. doi: 10.1371/journal.pbio.3003301. eCollection 2025 Jul.
3
Effectorless Fc-fusion improves FLT3L drug-like properties for cancer immunotherapy combinations.

本文引用的文献

1
A reservoir of stem-like CD8 T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response.肿瘤引流淋巴结中储存的类 CD8 T 细胞干细胞维持了持续的抗肿瘤免疫反应。
Sci Immunol. 2021 Oct;6(64):eabg7836. doi: 10.1126/sciimmunol.abg7836. Epub 2021 Sep 2.
2
The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes.PD-1/PD-L1 检查点抑制肿瘤引流淋巴结中的 T 细胞免疫。
Cancer Cell. 2020 Nov 9;38(5):685-700.e8. doi: 10.1016/j.ccell.2020.09.001. Epub 2020 Oct 1.
3
A scalable SCENIC workflow for single-cell gene regulatory network analysis.
无效应的Fc融合改善了用于癌症免疫治疗联合疗法的FLT3L的类药物特性。
EBioMedicine. 2025 Jul 5;118:105822. doi: 10.1016/j.ebiom.2025.105822.
4
Tumor cell spheroid-induced suppression of primary human cytotoxic T cells as a scalable model of exhaustion.肿瘤细胞球体诱导的原代人细胞毒性T细胞抑制作为一种可扩展的耗竭模型。
Immunother Adv. 2025 Jun 11;5(1):ltaf023. doi: 10.1093/immadv/ltaf023. eCollection 2025.
5
In vivo labelling resolves distinct temporal, spatial, and functional properties of tumour macrophages, and identifies subset-specific effects of PD-L1 blockade.体内标记解析了肿瘤巨噬细胞不同的时间、空间和功能特性,并确定了程序性死亡受体配体1(PD-L1)阻断的亚群特异性效应。
Cancer Immunol Res. 2025 Jun 16. doi: 10.1158/2326-6066.CIR-24-1233.
6
Beyond the tumor microenvironment: Orchestrating systemic T‑cell response for next‑generation cancer immunotherapy (Review).超越肿瘤微环境:为下一代癌症免疫疗法协调全身T细胞反应(综述)
Int J Oncol. 2025 Jul;67(1). doi: 10.3892/ijo.2025.5762. Epub 2025 Jun 13.
7
Enhancer-driven gene regulatory networks reveal transcription factors governing T cell adaptation and differentiation in the tumor microenvironment.增强子驱动的基因调控网络揭示了在肿瘤微环境中控制T细胞适应性和分化的转录因子。
Immunity. 2025 Jul 8;58(7):1725-1741.e9. doi: 10.1016/j.immuni.2025.04.030. Epub 2025 May 26.
8
Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion.帕博西尼与双链RNA传感器协同作用,通过内质网应激和免疫逃逸调节增强抗癌效果。
Nat Commun. 2025 May 25;16(1):4855. doi: 10.1038/s41467-025-60133-5.
9
IGM-7354, an Immunocytokine with IL15 Fused to an Anti-PD-L1 IgM, Induces NK and CD8+ T cell-Mediated Cytotoxicity of PD-L1-Positive Tumor Cells.IGM-7354,一种将白细胞介素15与抗程序性死亡配体1 IgM融合的免疫细胞因子,可诱导自然杀伤细胞和CD8 + T细胞介导的程序性死亡配体1阳性肿瘤细胞的细胞毒性。
Cancer Immunol Res. 2025 Aug 1;13(8):1172-1189. doi: 10.1158/2326-6066.CIR-24-0937.
10
Lymphatic chain gradients regulate the magnitude and heterogeneity of T cell responses to vaccination.淋巴链梯度调节T细胞对疫苗接种反应的强度和异质性。
J Exp Med. 2025 Aug 4;222(8). doi: 10.1084/jem.20241311. Epub 2025 Apr 30.
可扩展的单细胞基因调控网络分析 SCENIC 工作流程。
Nat Protoc. 2020 Jul;15(7):2247-2276. doi: 10.1038/s41596-020-0336-2. Epub 2020 Jun 19.
4
CCL2 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Shows Divergent Prognostic Potential for Bladder Cancer Patients Depending on Lymph Node Stage.肿瘤细胞和肿瘤浸润免疫细胞中CCL2的表达对膀胱癌患者的预后潜力因淋巴结分期而异。
Cancers (Basel). 2020 May 15;12(5):1253. doi: 10.3390/cancers12051253.
5
Beta cell-specific CD8 T cells maintain stem cell memory-associated epigenetic programs during type 1 diabetes.胰岛β细胞特异性 CD8 T 细胞在 1 型糖尿病中维持与干细胞记忆相关的表观遗传程序。
Nat Immunol. 2020 May;21(5):578-587. doi: 10.1038/s41590-020-0633-5. Epub 2020 Mar 30.
6
Trajectory-based differential expression analysis for single-cell sequencing data.基于轨迹的单细胞测序数据分析。
Nat Commun. 2020 Mar 5;11(1):1201. doi: 10.1038/s41467-020-14766-3.
7
NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors.NOX4 抑制作用通过克服肿瘤中癌症相关成纤维细胞介导的 CD8 T 细胞排除作用增强免疫治疗。
Cancer Res. 2020 May 1;80(9):1846-1860. doi: 10.1158/0008-5472.CAN-19-3158. Epub 2020 Mar 2.
8
Peripheral T cell expansion predicts tumour infiltration and clinical response.外周 T 细胞扩增可预测肿瘤浸润和临床反应。
Nature. 2020 Mar;579(7798):274-278. doi: 10.1038/s41586-020-2056-8. Epub 2020 Feb 26.
9
PD-1+ stemlike CD8 T cells are resident in lymphoid tissues during persistent LCMV infection.在持续的 LCMV 感染期间,PD-1+ 类干细胞 CD8 T 细胞存在于淋巴组织中。
Proc Natl Acad Sci U S A. 2020 Feb 25;117(8):4292-4299. doi: 10.1073/pnas.1917298117. Epub 2020 Feb 7.
10
An intra-tumoral niche maintains and differentiates stem-like CD8 T cells.肿瘤内龛位维持并分化具有干细胞样特征的 CD8+T 细胞。
Nature. 2019 Dec;576(7787):465-470. doi: 10.1038/s41586-019-1836-5. Epub 2019 Dec 11.